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Introduction: This case of giant cell arteritis is noteworthy because it evaded standard diagnostic criteria and only
emerged as fever of unknown origin. In this regard, we present 18F-fluorodeoxyglucose positron emission
tomography as a valid diagnostic method.
Case presentation: This case report describes a 58-year-old Caucasian woman who is a cigarette smoker with a
10-week history of fever of unknown origin, night sweats and weight loss of 12kg. Initially, clinical presentation was
suspicious of malignant disease. Laboratory findings detected significantly elevated inflammatory blood parameters
including C-reactive protein and elevated erythrocyte sedimentation rate (110mm/hour). Extensive diagnostic
workup including microbiological and rheumatological assessment, ultrasonography, endoscopy and computed
tomography of abdomen and thorax did not indicate any septic or malignant focus. Eventually, 18F-fluorodeoxyglucose
positron emission tomography was able to reveal arteritis of her aortic arch and supraaortic branches. Subsequently,
she commenced steroid and methotrexate therapy that led to sustained remission.
Conclusions: This case of giant cell arteritis may promote discussion regarding a more specific classification for this
disease entity. Furthermore, it confirms that 18F-fluorodeoxyglucose positron emission tomography might serve as a
valuable tool for diagnosis of giant cell arteritis, because it could facilitate an accurate and non-invasive detection of
lesions of large vessels.
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Giant cell arteritis (GCA) is the most common rheumato-
logical vasculopathy in Caucasians in Europe [1]. Clinical
findings comprise new onset of temporal headache, jaw
claudication, visual loss, temporal artery induration, thor-
acic aortic aneurysm or intense pain in pectoral and pelvic
girdle with morning stiffness [2]. In addition, systemic
symptoms including fatigue, weight loss or fever occur in
up to 50%. Furthermore, GCA may be the cause of fever
of unknown origin (FUO) in up to 17% of patients with
FUO above 50 years of age [3,4]. A retrospective study of* Correspondence: markus.brueckner@ukmuenster.de
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[5]; fever can be the single presenting symptom.
In contrast to common presentations of GCA, we de-
scribe an exceptional clinical course presenting with FUO
as the only clinical feature in the absence of other usual
clinical characteristics.
Case presentation
A 58-year-old Caucasian obese woman (body mass index
31.5kg/m2) was admitted to our hospital with a history
of continuous FUO varying from 38°C to 39.5°C for 10
weeks despite several courses of antibiotic therapy. Her
history included 30 pack years of cigarette smoking.
Currently, she suffered from night sweats, continuous
weight loss of 12kg and dyspnea on exertion. No signsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pecially no temporal pain, headache or visual impairment.
There were no skin lesions, no myalgia of pectoral or
pelvic girdle or morning stiffness, and no arthralgia.
Her blood pressure was 140/90mmHg on both arms.
Initial suspected diagnosis involved malignant or infec-
tious diseases. Laboratory findings showed elevated sys-
temic parameters of inflammation including C-reactive
protein (CRP; 22mg/dL) and accelerated erythrocyte se-
dimentation rate (ESR; 110mm/hour). Complete blood
count showed total white blood cell 13.8/μL, total red
blood cell 5 million/μL, hemoglobin 13.4g/dL, hematocrit
42.8%, mean corpuscular volume 84.4fL, mean corpus-
cular hemoglobin 26.4pg, mean corpuscular hemoglobin
concentration 31.3g/dL, and platelet 278,000/μL. Differen-
tial blood count showed neutrophil granulocytes 88.1%,
lymphocytes 8.1%, monocytes 3.6%, eosinophil granulo-
cytes 0.1%, and basophil granulocytes 0.5%. Mean plate-
let volume was 10.4fL. Serum albumin showed 32.8g/L
and β2 microglobulin 1.9mg/L. Detailed blood tests for
rheumatic disorders were negative. Repeated microbio-
logical blood tests, stool cultures as well as serological test-
ing for specific pathogens, including Orthomyxoviridae,
Herpesviridae, Mycobacteriaceae, Legionellaceae, Spiro-
chaetaceae, Chlamydiaceae and Mycoplasmataceae were
negative.
Endoscopic evaluations, including bronchoscopy, eso-
phagogastroduodenoscopy and colonoscopy as well asFigure 1 18F-fluorodeoxyglucose positron emission tomography who
increased metabolic activity (maximal standardized uptake value 3.0, mean
increased glucose metabolism in the aortic arch (arrow heads) too. No oth
this imaging.transesophageal echocardiography were without patho-
logical findings. In addition, computed tomography (CT)
of her thorax and abdomen showed atherosclerotic le-
sions only; however, no evidence of any inflammatory or
malignant focus was detected. In particular, there were
no alterations of the vessel wall indicative of inflam-
mation. We decided to perform 18F-fluorodeoxyglucose
positron emission tomography (18F-FDG PET; Figure 1).
18F-FDG PET demonstrated increased metabolic activity
in her supraaortic arteries with the most intense involve-
ment of the subclavian arteries and also slightly eleva-
ted glucose metabolism in the aortic arch. A borderline
asymmetry of the femoral artery was regarded as within
physiological limits. There were no additional foci of in-
creased glucose metabolism in her body. Thus, GCA of
the supraaortic arteries was proposed as the inflamma-
tory focus. Other causes for aortitis or arteritis (Gsell-
Erdheim disease, syphilitic aortitis) and FUO had been
excluded initially. After commencement of steroid the-
rapy with 90mg prednisolone daily intravenously, her
inflammatory markers dropped rapidly within 10 days
(CRP 6mg/dL) and she was discharged in good health.
Over a period of 6 weeks steroids were reduced to the
lowest effective dose of 40mg daily orally with parameters
of disease being clinical symptoms, CRP, and ESR. Metho-
trexate was added at a dose of 20mg weekly subcutaneous
injection to support steroid tapering. Today, she consults
our rheumatologic out-patient clinic at intervals of 6le-body image. In particular, subclavian arteries (arrows) show
liver standardized uptake value 1.8). The oblique projection shows
er foci of increased metabolism like solid tumors were detectable in
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prednisolone daily and methotrexate 20mg weekly sub-
cutaneous injection.
Discussion
Our case clearly shows the limitations of 1990 American
College of Rheumatology criteria for GCA [6]: age over
50 years, new onset of localized headache, temporal ar-
tery tenderness, elevated ESR for more than 50mm/hour
and biopsy sample showing necrotizing arteritis with
giant cells. Weyand and Goronzy [7] report blindness,
headache and jaw claudication as the classical clinical
symptoms in cranial arteritis. However, rather systemic
characteristics of GCA such as night sweats, loss of
weight, and in particular FUO can be the only present-
ing symptoms, highlighting the necessity of a more
specific classification. Weyand et al. [8,9] suggested
clinical subtypes of GCA affecting distinct vascular
territories with different patterns of cytokine production,
leading to occlusive or non-occlusive disease and differ-
ent features in temporal artery biopsy. These subtypes
are cranial arteritis, large vessel arteritis or aortitis, isolated
polymyalgia rheumatica and, as depicted in the present
case, systemic inflammatory syndrome with arteritis.
If GCA presents as systemic inflammatory syndrome
only, then FUO diagnostics provoke high costs for
diagnostic management and duration of hospitalization
[10,11]. As the causes for FUO are numerous and het-
erogeneous, there is no gold standard in the diagnostic
process. Since FUO is well known to be a possible
symptom in patients with GCA, temporal artery biopsy
is crucial in the diagnostic workup after initial negative
findings [12]. Biopsy is still recommended as the gold
standard as a sophisticated procedure in local anesthe-
sia with low complication rates; however, only 50% of
biopsy samples show multinucleated giant cells with
even 10 to 25% false negative results [13]. Moreover,
even the combination of FUO and asymptomatic thor-
acic manifestations such as pleural effusions may be
presenting symptoms of GCA [14]. Because of its clinical
heterogeneity, initial diagnosis of GCA and evaluation of
its extent remain challenging, leading to specific advan-
tages and disadvantages of conventional imaging proce-
dures such as CT and magnetic resonance imaging [15].
In obscure cases like ours, nuclear imaging as a second
line of diagnostic provides high standards concerning
sensitivity and specificity [16,17] helping to identify the
cause of fever. In our patient, inflammation of the aortic
arch and subclavian arteries could only be visualized by
18F-FDG PET.
Recently, it could be shown that 18F-FDG PET provides
a high level of effectiveness in assessing initial diagnosis,
extent and activity of GCA [18,19]. Other nuclear me-
thods such as gadolinium scanning are also available fordetection of vascular wall inflammation, although they
possess less sensitivity and specificity. However, there are
several limitations of 18F-FDG PET, which cannot reliably
be used to diagnose or monitor inflammation of the tem-
poral artery due to the limited spatial resolution of PET
alone; the combination of PET and CT (PET-CT) gener-
ally has superior spatial resolution. For this reason, PET
cannot replace temporal artery biopsy if the disease is lim-
ited to the temporal arteries [20]. Finally, atherosclerosis
as the most frequent inflammatory disease of the arteries
is the most important differential diagnostic feature of in-
creased tracer uptake in the blood vessels.
Conclusions
In the case presented here, classical clinical characteris-
tics of GCA were missing, while FUO was the leading
symptom. Finally, our case proves that 18F-FDG PET is
able to serve as a valuable tool for diagnosis of GCA.
18F-FDG PET can be a valid diagnostic method when
manifestations such as vascular insufficiency are lacking.
In addition, new criteria for the classification of GCA
are needed to detect this disease at early stage.
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